Evidence map›Paper›PMID 28179428›Full record

ArticleThe Journal of biological chemistry2017

Unconventional Peptide Presentation by Major Histocompatibility Complex (MHC) Class I Allele HLA-A*02:01: BREAKING CONFINEMENT.

Soumya G Remesh, Massimo Andreatta, Ge Ying, Thomas Kaever, Morten Nielsen, Curtis McMurtrey, William Hildebrand, Bjoern Peters, Dirk M Zajonc

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. The pockets guide to HLA class I molecules.Biochemical Society transactions · 2021
    Review
  10. Article
  11. Review
  12. Overlapping Peptides Elicit Distinct CD8Journal of immunology (Baltimore, Md. : 1950) · 2020
    Article
  13. Article
  14. T Cell Epitope Predictions.Annual review of immunology · 2020
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Soumya G RemeshFrom the Division for Cell Biology and.
Massimo AndreattaDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037.
Ge YingFrom the Division for Cell Biology and.
Thomas KaeverDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037.
Morten NielsenInstituto de Investigaciones Biotecnológicas, Universidad Nacional de San Martín, CP1650 San Martín, Argentina.
Curtis McMurtreyDepartment of Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma 73104.
William HildebrandDepartment of Microbiology and Immunology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma 73104.
Bjoern PetersDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, La Jolla, California 92037.
Dirk M ZajoncFrom the Division for Cell Biology and dzajonc@lji.org.
La Jolla Institute for Immunology · USGhent University · BENational University of General San Martín · ARTechnical University of Denmark · DKTexas Historical Commission · USUniversity of Oklahoma Health Sciences Center · US

Funding

Translation of immunologic technologies from basic research into pre-clinical nonU19AI062629 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI COGGESHALL, KENNETH MARK · 2004 to 2023
$56.2M
ZWITTERION SURFACTANT DDMAB FOR IMPROV STABIL OF PROTEINP41RR001209 · NCRR · STANFORD UNIVERSITY · PI REESE, MICHAEL LLOYD · 1985 to 2011
$38.9M
X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6M
Design and evaluation of HLA-A, -B, and -C binding peptides that disrupt inhibitory KIR/MHC interaction and activate NK cellsR21AI128609 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI ZAJONC, DIRK M · 2017 to 2018
$495k
NCRR NIH HHS P41 RR001209NIAID NIH HHS HHSN272201200010CNIAID NIH HHS R21 AI128609NIAID NIH HHS U19 AI062629NIGMS NIH HHS P41 GM103393
6 · The paper itself

Abstract

Peptide antigen presentation by major histocompatibility complex (MHC) class I proteins initiates CD8

Indexed as

AllelesAmino AcidsAntigen PresentationBinding SitesHistocompatibility Antigens Class IIHLA-A2 AntigenHumansPeptidesProtein BindingProtozoan ProteinsToxoplasmaAmino AcidsHistocompatibility Antigens Class IIHLA-A*02:01 antigenHLA-A2 AntigenPeptidesProtozoan Proteinsantigen presentationmajor histocompatibility complex (MHC)natural killer cells (NK cells)peptide interactionprotein crystallizationprotein structureT-cell receptor (TCR)Toxoplasma gondii

Identifiers

PMID28179428
PMCPMC5392673
OpenAlexW2586893617

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.